CN111328279B - 口服利福霉素sv组合物 - Google Patents

口服利福霉素sv组合物 Download PDF

Info

Publication number
CN111328279B
CN111328279B CN201880072798.7A CN201880072798A CN111328279B CN 111328279 B CN111328279 B CN 111328279B CN 201880072798 A CN201880072798 A CN 201880072798A CN 111328279 B CN111328279 B CN 111328279B
Authority
CN
China
Prior art keywords
pharmaceutical composition
oral pharmaceutical
rifamycin
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880072798.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111328279A (zh
Inventor
卢吉·摩洛
卢吉·玛丽亚·隆戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of CN111328279A publication Critical patent/CN111328279A/zh
Application granted granted Critical
Publication of CN111328279B publication Critical patent/CN111328279B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880072798.7A 2017-11-10 2018-11-07 口服利福霉素sv组合物 Active CN111328279B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584226P 2017-11-10 2017-11-10
US62/584,226 2017-11-10
PCT/IB2018/058748 WO2019092614A1 (en) 2017-11-10 2018-11-07 Oral rifamycin sv compositions

Publications (2)

Publication Number Publication Date
CN111328279A CN111328279A (zh) 2020-06-23
CN111328279B true CN111328279B (zh) 2023-04-14

Family

ID=64426987

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072798.7A Active CN111328279B (zh) 2017-11-10 2018-11-07 口服利福霉素sv组合物

Country Status (17)

Country Link
US (3) US11564883B2 (https=)
EP (3) EP4438039A3 (https=)
JP (2) JP2021502382A (https=)
KR (1) KR102747348B1 (https=)
CN (1) CN111328279B (https=)
AR (1) AR114140A1 (https=)
AU (1) AU2018364617B2 (https=)
BR (1) BR112020009171A2 (https=)
CA (1) CA3078900A1 (https=)
DK (1) DK3706724T3 (https=)
ES (1) ES2989706T3 (https=)
FI (1) FI3706724T3 (https=)
IL (1) IL274414B2 (https=)
MX (1) MX2020004706A (https=)
PL (1) PL3706724T3 (https=)
WO (1) WO2019092614A1 (https=)
ZA (1) ZA202002726B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022102198A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 内服固形剤
US20220280478A1 (en) * 2021-03-05 2022-09-08 Bausch Health Ireland, Limited Methods of using rifamycin sv for the treatment of sickle cell disease
EP4412588A1 (en) * 2021-10-05 2024-08-14 Cosmo Technologies Ltd An in-situ gelling enema of rifamycin for treating pouchitis and distal ulcerative colitis
WO2025064599A1 (en) * 2023-09-19 2025-03-27 The United States Government As Represented By The Department Of Veterans Affairs Rifamycin composition for treating sarcopenia
WO2025157240A1 (zh) * 2024-01-26 2025-07-31 丹诺医药（苏州）股份有限公司 化合物用于制备治疗细菌代谢相关疾病的药物的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
CA2377301C (en) 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
KR20080081351A (ko) 2006-01-04 2008-09-09 도꾜 메디칼 앤드 덴탈 유니버시티 간장 질환 치료제 및 간기능 개선제
BRPI0908026B8 (pt) 2008-02-26 2021-05-25 Salix Pharmaceuticals Ltd uso de rifaximina no tratamento de doenças do intestino
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US8741048B2 (en) 2011-08-30 2014-06-03 Brother Kogyo Kabushiki Kaisha Water-based ink for ink-jet recording and ink cartridge
IN2014DN06662A (https=) 2012-02-13 2015-05-22 Cosmo Technologies Ltd
WO2016003536A1 (en) 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
WO2017053885A1 (en) * 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
胡崇茂编著.薄膜包衣预混剂生产和应用.《药用辅料 薄膜包衣预混剂生产和应用》.中国医药科技出版社,2014, *

Also Published As

Publication number Publication date
AR114140A1 (es) 2020-07-29
PL3706724T3 (pl) 2024-12-16
AU2018364617B2 (en) 2024-11-07
KR20200086285A (ko) 2020-07-16
EP4438039A3 (en) 2024-12-04
JP2021502382A (ja) 2021-01-28
MX2020004706A (es) 2020-09-07
RU2020119035A (ru) 2021-12-10
ES2989706T3 (es) 2024-11-27
WO2019092614A1 (en) 2019-05-16
US12036316B2 (en) 2024-07-16
IL274414B2 (en) 2024-08-01
CN111328279A (zh) 2020-06-23
US11564883B2 (en) 2023-01-31
CA3078900A1 (en) 2019-05-16
US20240398699A1 (en) 2024-12-05
DK3706724T3 (da) 2024-10-14
EP4431094A3 (en) 2024-11-20
EP3706724B1 (en) 2024-09-11
IL274414B1 (en) 2024-04-01
JP2023112076A (ja) 2023-08-10
ZA202002726B (en) 2024-09-25
FI3706724T3 (fi) 2024-10-14
AU2018364617A1 (en) 2020-05-07
EP3706724A1 (en) 2020-09-16
IL274414A (en) 2020-06-30
US20200281850A1 (en) 2020-09-10
RU2020119035A3 (https=) 2022-04-20
JP7651620B2 (ja) 2025-03-26
KR102747348B1 (ko) 2024-12-31
BR112020009171A2 (pt) 2020-11-03
EP4431094A2 (en) 2024-09-18
US20230135346A1 (en) 2023-05-04
EP4438039A2 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
JP7422827B2 (ja) コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US12036316B2 (en) Oral rifamycin SV compositions
EP3923943B1 (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
JP2021138778A (ja) アンチセンス組成物およびその作製および使用
US20130259906A1 (en) Pharmaceutical composition comprising one or more fumaric acid esters
US20090252708A1 (en) Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
HK1259347A1 (zh) 治疗结肠炎的方法
EP3684344B1 (en) Delayed release deferiprone tablets and methods of using the same
CN108289870A (zh) 治疗特定患者群体的神经变性病症的方法
CN104394691A (zh) 用5-氨基水杨酸治疗过敏性肠道综合症的组合物和方法
JP2023550994A (ja) Ｃｏｖｉｄ－１９及びその他のウイルス感染症の患者の症状の消散までの時間を低減するためのニコチンアミド、ニコチンアミド前駆体及びニコチンアミド代謝体並びにそれらの組成物
RU2793319C2 (ru) Композиции рифамицина sv для перорального применения
HK40110949A (en) Oral rifamycin sv compositions
HK40110239A (en) Oral rifamycin sv compositions
HK40036103A (en) Oral rifamycin sv compositions
HK40036103B (en) Oral rifamycin sv compositions
JP2013518915A (ja) ペントキシフィリンの便秘の予防または治療における応用
JP2025511241A (ja) 感染症の１種又は複数の急性期後症状を予防又は低減するためのニコチンアミド、ニコチンアミド前駆体、ニコチンアミド代謝体又はその組合せを含む組成物
HK40065061A (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
HK40065061B (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
EA042135B1 (ru) Таблетка деферипрона с отсроченным высвобождением и способ ее изготовления

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant